This article contains general information only and should not be used as a substitute for professional diagnosis, treatment or care by a qualified health care provider
How is microdosing different from starting with the standard dose
Originally developed for diabetes management, these GLP-1 receptor agonists have shown impressive results in clinical trials helping many patients lose 1521% of their body weight under controlled study conditions
This is referred to as delayed gastric emptying
258 Multiple studies have demonstrated anti-inflammatory actions, such as reduction of secretion of pro-inflammatory cytokines or increase in the secretion of anti-inflammatory cytokines, of GLP-1R agonists, 259 which may have future therapeutic applications for both T1D and T2D, as well as inflammatory/autoimmune diseases
In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
